Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03565341 · ClinicalTrials.gov registry record · NA
Efficacy and Safety of PiQo4 Device for Treatment of Melasma
A NA study of Melasma, sponsored by Focus Medical.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03565341 is a NA study of Melasma that has completed, run by Focus Medical. The registered enrollment target is 20 participants, below the 43-participant average among 8 other Melasma trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03565341, a NA study of Melasma, has completed, sponsored by Focus Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Single center, Prospective, Open Label with Split-face Study Design. Face sides will be randomized to receive either 1064nm alone or 1064nm \& 585nm combination treatment. Each subject will receive up to 3 treatments at monthly intervals (±4 days). Follow-up visits will take place at 1, 3, and 6 months following the last treatment.
Conditions Studied
Interventions
- DEVICE PiQo4
Study Locations (1)
New Jersey
- Hackensack University Medical Center - Skin Laser & Surgery Specialists Of NY & NJ - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-07-02 |
| Est. Completion | 2019-08-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03565341
The ClinicalTrials.gov registry entry for NCT03565341 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 43-participant average among 8 other Melasma trials with a reported enrollment target (53% lower). The listed sponsor is Focus Medical, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melasma appearing as the primary indexed condition, and to 1 intervention - of which PiQo4 is the first listed.
NCT03565341 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT03565341 about?
NCT03565341 is a clinical study titled "Efficacy and Safety of PiQo4 Device for Treatment of Melasma". Single center, Prospective, Open Label with Split-face Study Design. Face sides will be randomized to receive either 1064nm alone or 1064nm \& 585nm combination treatment. Each subject will receive up to 3 treatments at monthly intervals (±4 days). Follow-up visits will take place at 1, 3, and 6 mo...
What is the current status of trial NCT03565341?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2018-07-02. Estimated completion is 2019-08-08.
What conditions does trial NCT03565341 study?
This clinical trial studies the following conditions: Melasma.
What interventions are being tested in trial NCT03565341?
The interventions under investigation include: PiQo4 (DEVICE).
Who is sponsoring clinical trial NCT03565341?
This trial is sponsored by Focus Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03565341 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melasma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sylfirm X Radiofrequency Microneedling for the Treatment of Melasma
RECRUITING · NA
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
-
LaseMD System for the Treatment of Melasma
ACTIVE NOT RECRUITING · NA
-
Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma
COMPLETED · NA
-
A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma
COMPLETED · NA
-
Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.